Hyperhomocysteinemia and restenosis

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 8, Issue 1, 2001, Pages 9-13

  Kumbasar, Deniz ^a   Dinçer, Irem ^a   Ertas, Fatih ^a   Güleç, Sadi ^a   Erol, Cetin ^a   Akyürek, Ã mer ^a   Kiliçkap, Mustafa ^a   Oral, Dervis ^a   Sipahi, Emine ^b   Laleli, Yahya ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b Duzen Laboratories   (Turkey)

Author keywords

homocysteine; percutaneous transluminal coronary angioplasty; restenosis; stents

Indexed keywords

HOMOCYSTEINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR RISK; CORONARY ARTERY DILATATION; CORONARY STENT; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RECURRENCE; RISK FACTORS; STENTS;

EID: 17744373259     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182670100800102     Document Type: Article

References (41)

1. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111–128.
2. Montalescot G. Homocysteine: The new player in the field of coronary risk. Heart 1996; 76: 101–102.
3. Tokgözoğlu SL, Alikaşifoğlu M, Ünsal I, Atalar E, Aytemir K, Ozer N, et al Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate. Heart 1999; 81: 518–522.
4. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease and drug therapy. J Lab Clin Med 1989; 114: 473–501.
5. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386–389.
6. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992; 12: 279–298.
7. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877–881.
8. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496–501.
9. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al A comparison of balloon expandable stent with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489–495.
10. de Belder A, Thomas MR. The pathophysiology and teatment of in-stent restenosis. Stent 1998; 1: 74–82.
11. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Geligonul U, Topol EJ, Bulle TM, et al Coronary angiographic and clinical determinants of procedural outcome with multivessel coronary artery disease: Implications for patient selection. Circulation 1990; 82: 1193–1202.
12. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery stenosis: Percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61–68.
13. Colombo A. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676–1688.
14. Klugherz BD, DeAngelo DL, Kim BK, Herrmann HC, Hirshfeld JW, Kolansky DM. Three-year clinical follow-up after Palmaz-Schatz stenting. J Am Coll Cardiol 1996; 27: 1186–1191.
15. Carozza J, Kuntz R, Schatz R, Leon M, Goldberg S, Savage M, et al Inter-series differences in the restenosis rate of Palmaz-Schatz coronary stent placement: Differences in demographics and post-procedure lumen diameter. Cathet Cardiovasc Diagn 1994; 31: 173–178.
16. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, et al Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428–1436.
17. Kasaoka S, Tobis JM, Akiyama T, Reimers B, Di Mario C, Wong ND, et al Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol 1998; 32: 1630–1635.
18. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular disease? N Engl J Med 1995; 332: 328–329.
19. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordreehaug JE. Serum total homocystein and coronary artery disease. Int J Epidemiol 1995; 24: 704–709.
20. Meleady RA, Mulcahy DA, Graham IM. Genes, greens and homocysteine. Heart 1996; 76: 103–104.
21. Daly L, Robinson K, Tan KS, Graham IM. Hyperhomocysteinemia: A metabolic risk factor for coronary heart disease determined by both genetic and environmental influences? Q J Med 1993; 86: 685–859.
22. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731–741.
23. James TN. The spectrum of diseases of small coronary arteries and their physiologic consequences. J Am Coll Cardiol 1990; 15: 763–774.
24. Welch GN, Upchurch GR Jr, Loscalzo J. Hyperhpcyst(e)ineima and atherothrombosis. Ann N Y Acad Sci 1997; 811: 48–58.
25. Anderson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem 1995; 41: 361–366.
26. Starkebaum G, Harlan JM. Endothelial cell injury due to copper catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370–1376.
27. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, et al Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854–858.
28. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al Adverse vascular effects of homocysteine are modulated by endothelium dependent relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308–318.
29. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895–901.
30. Ratnoff OD. Activation Hageman factor by L-homocysteine. Science 1968; 162: 1007–1009.
31. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909–1916.
32. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906–1914.
33. Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia: Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537–543.
34. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study. Circulation 1996; 94: 1247–1254.
35. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–236.
36. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assesment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049–1057.
37. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: Systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5: 229–232.
38. Tsakiris DA, Tschöpl M, Jager K, Haefeli WE, Wolf F, Marbet GA. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis 1999; 142: 193–200.
39. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inemia. Lancet 1998; 351: 263. (letter).
40. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation 1999; 99: 178–182.
41. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, et al Homocysteine and risk of premature coronary artery disease: Evidence of common gene mutation. Circulation 1996; 94: 2154–2158.